Related Experiment Video
Updated: Jul 4, 2025
09:06
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
1.5K
Integration of PET in DLBCL
Katharine L Lewis1, Judith Trotman2
1Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Seminars in Hematology
|February 7, 2024
Summary
18F-fluorodeoxyglucose positron emission tomography-computerized tomography (FDG-PET/CT) is the gold standard for lymphoma imaging. This review highlights FDG-PET/CT
Area of Science:
- Nuclear medicine imaging
- Oncologic imaging
- Lymphoma diagnostics
Background:
- 18F-fluorodeoxyglucose positron emission tomography-computerized tomography (FDG-PET/CT) is the established standard for lymphoma staging and response assessment.
- Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive non-Hodgkin lymphoma requiring precise management strategies.
Approach:
- This review synthesizes current literature on the application of FDG-PET/CT in DLBCL.
- It examines the modality's established roles and explores emerging applications.
Key Points:
- FDG-PET/CT is crucial for initial staging of DLBCL, determining disease extent.
- It plays a vital role in interim and end-of-treatment response assessment, guiding therapeutic decisions.
- Interim FDG-PET/CT findings can predict treatment outcomes and inform risk stratification.
Conclusions:
- FDG-PET/CT is indispensable for comprehensive DLBCL management, from staging to response evaluation.
- Its utility extends to prognostication, offering valuable insights into patient outcomes.
- Future research may further expand the role of FDG-PET/CT in personalized DLBCL therapy.
